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such as bulleous diseases, connective
tissue diseases and severe cutaneous
drug reactions. This category was
assigned the health state ‘‘disfigurement
level 1,’’ which has the disability weight
0.013 indicating that the true loss of
YLD in the population is even higher.
Functional health loss and psychological
impact of skin conditions
In the GBD 2010 study, the disability
weights of the 220 unique health states
were re-estimated using face-to-face or
telephone surveys among 13,000 indi-
viduals in five different countries and an
open-access web-based survey among
16,000 individuals (Salomon et al.,
2012). This is a huge improvement
compared to the previous ‘‘one size,
fits all’’ disability weight of 0.056,
which was estimated by a small panel
of health experts (World Health Organi-
zation, 2004). In the GBD 2010 study,
seven different weights (ranging from
0.013 to 0.562, excluding skin cancer),
which were depend on disease severity,
were included. The current disability
weights quantify functional health loss
to make a clear distinction between
health and wellbeing. Although this
approach was chosen to explicitly
quantify health loss rather than welfare
loss, the exclusion of the psychological
burden leads to an underestimation of
the true non-fatal burden in the popula-
tion. This underestimation is especially
true for skin conditions because the
psychological burden of skin diseases
can be substantial (Ahmed et al.,
2013). Also, the reduction of 1,160
sequelae to 220 unique health states
was needed to for feasibility reasons,
but may have led to an oversimpli-
fication. For example, melanoma and
NMSC were assigned the same disabi-
lity weights as well as all other cancers,
while the psychological impact is likely
to be very different.
Individual burden versus population
burden
The estimation of the YLD of a disease
depends on the prevalence and the
severity of a disease. Many of the
selected skin conditions have a relatively
mild impact on patient’s lives in the
majority of all patients, such as eczema
and acne vulgaris. However, due to the
very high prevalence of these skin dis-
eases, the burden (YLD) on a population
level is enormous. From a public health
perspective, these diseases are of interest
because they represent a high YLD, but
many clinicians may argue that a focus
on disease with a higher individual
disease burden, but low YLD, require
more attention (e.g., bulleous diseases,
connective tissue diseases and severe
cutaneous drug reactions). This potential
conflict between population and indivi-
dual perspective, and thus prioritization,
is in line with what is often seen in cost-
effectiveness evaluations of health care
interventions. As a society we should
answer the question if we would we like
to treat many people who can cope with
their skin condition or if we would like
to treat a small number of people who
experience a high disability due to their
skin disease?
Conclusion
What physicians who treat patients with
skin diseases have known for a long time
(i.e., ‘‘you hardly ever die from a skin
disease, but it can be truly bothersome’’)
has now been empirically confirmed:
skin diseases are an important cause of
health loss on a global level. The find-
ings of this beautiful study stimulates
researchers to further assess and refine
the specific impact of skin diseases in
order to monitor (reductions) of health
loss due to skin conditions in the future.
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22 Again: IL-22 as a Risk Gene and
Important Mediator in Psoriasis
Andrew Johnston1 and Johann E. Gudjonsson1
IL-22 targets our external epithelial barriers, bolstering our defenses, and has long
been implicated in the pathogenesis of psoriasis. Nikamo and colleagues (2014)
identify a haplotype in the IL22 promoter with a strong association to juvenile-onset
psoriasis and demonstrate that this risk variant is associated with increased IL-22
production by T cells. We explore the implications of this work.
Journal of Investigative Dermatology (2014) 134, 1501–1503; doi:10.1038/jid.2014.81
IL-22 is a cytokine that targets our
external epithelial barriers such as those
of the lungs, gastrointestinal (GI) tract,
and the skin, bolstering our defenses
against external insults. Moreover,
IL-22 has long been implicated in the
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pathogenesis of psoriasis. In this issue,
Nikamo et al. (2014) show that by
stratifying their cohort of psoriasis
patients according to age at onset, they
could identify a high-risk haplotype in
the IL22 promoter that showed a strong
association with onset of psoriasis
before the age of 10. Further, the
authors show that the same haplotype
gives rise to enhanced production of
IL-22. This could be highly important,
as serum IL-22 levels, skin IL-22 mRNA,
and numbers of IL-22þ cells in the skin
have been shown to correlate with
disease severity (Boniface et al., 2007;
Lo et al., 2010), and strongly suggests
that patients with this genotype might
have a higher risk of more extensive
and severe disease. This is likely to be
one avenue of research that will follow
these interesting results in the near
future.
IL-22 is a member of the IL-10 family
of cytokines (along with IL-10, IL-19,
IL-20, IL-24, and IL-26), which are rela-
ted by their sequence and structural
similarities as well as their shared recep-
tor usage. Each IL-10 family cyto-
kine uses a heterodimeric receptor (see
Table 1) with IL-22 using the ubiqui-
tously expressed IL-10R2 together
with IL-22R1, a receptor with a highly
specific tissue expression pattern, and
expressed only by the skin, lung, and GI
epithelia, liver and pancreas cells, but
not by lymphocytes (Sabat et al., 2014).
This endows IL-22 with a tissue
specificity that contrasts with that of
IL-17, TNF-a, and IFN-g, where IL-22
can be thought of as acting as a terminal
effector cytokine with no direct effect
on immune cells.
In terms of skin biology, IL-22
has profound effects on epidermal
keratinocytes, inducing hyperplasia,
migration, and curtailing the normal
differentiation pathway as well as the
induction of a broad range of antimi-
crobial peptides (Boniface et al.,
2005), suggesting a role in promoting
wound healing and antimicrobial
responses (Figure 1). IL-22 has long
been suspected of having a crucial
role in the development of psoriasis
skin lesions. This cytokine, along
with the other IL-20 subfamily
members (Table 1), is abundantly
overexpressed in lesional psoriasis epi-
dermis as well as in the blood of
psoriasis patients (Boniface et al.,
2007) and is restored to normal
levels during effective treatment
(Wolk et al., 2006). Although in the
current work, no significant increase
in plasma IL-22 was demonstrated in
the high-risk haplotype group, this
could easily be the result of the
study being underpowered to detect
this, given the numbers of patients
enrolled.
IL-22 has somewhat defied the
paradigm of classification into the strict
Th1, Th2, and Th17 categories, with
IL-22 secretion reported from Th1,
Th17, and Tc22 (IL-22þCD8þ T) cells
as well as the more recently appreciated
Th22 cells that produce IL-22 in the
absence of IFN-g, IL-4, or IL-17. In
addition, several phenotypes of innate
immune cells have been reported
to produce IL-22, including natural
killer (NK) cells, gd-T cells, lymphoid
Table 1. IL-10 family cytokines
are related by structure and
receptor usage
Ligand Receptor complex
IL-10 IL-10R1þ IL-10R2
IL-19 IL-20R1 or IL-22R1þ IL-20R2
IL-20 IL-20R1 or IL-22R1þ IL-20R2
IL-22 IL-22R1þ IL-10R2
IL-24 IL-20R1 or IL-22R1þ IL-20R2
IL-26 IL-20R1þ IL-10R2
Clinical Implications
 A polymorphism in the promoter region of IL-22 is shown to be associated
with increased risk of psoriasis onset in childhood, and correlates with
increased production of IL-22.
 IL-22 levels have been shown in several studies to correlate with disease
severity, suggesting that patients with this risk polymorphism might be at
risk of more severe disease.
 These data indicate that psoriasis with onset in early childhood differs
from later-onset psoriasis and points toward increased stratification of
patients for both genetic and clinical studies.
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Figure 1. IL-22 is an important component of the cytokine network that drives psoriatic skin
inflammation. Genome-wide association studies (GWAS) have unearthed a number of polymorphisms
potentially affecting the function of several molecules in this network (red text). Although a genetic
association of IL22 and psoriasis has not been shown in several Caucasian GWAS, the impact of the
promoter polymorphism studied by Nikamo et al., 2014, as well as previously reported copy number
variations in IL22 and DEFB4, make this an intriguing discovery.
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tissue inducer cells, and type 3 innate
lymphoid cells (ILC3). As such Th17,
Th22, Tc22 T cells, ILC3, and NK
cells (reviewed in Sabat et al., 2014)
have all been reported to be increased
in number in psoriasis plaques. The
profound effects of IL-22 on skin are
further heightened by powerful
synergies with IL-17 and TNF, greatly
amplifying its effects as well as those of
IL-17 and TNF on the cytokine network
in psoriasis.
It is of interest that IL-22 is the direct
downstream effector cytokine of IL-23,
which is also influenced by psoriasis-
associated polymorphisms in both IL23R
and IL12B (coding the common p40
chain of IL-12 and IL-23). Moreover,
therapeutic targeting of the p40 chain
is highly effective. Given the impact of
IL-22 and its close relatives IL-20 and
IL-24 on the epidermis (Sa et al., 2007),
therapeutic targeting of the shared
IL-22R1 receptor might be more
effective than targeting IL-22 directly,
and has recently been proposed (Sabat
et al., 2014) and carries the advantage
of an intervention in which a cytokine
receptor with a restricted tissue expres-
sion would limit immune suppression
compared with targeting the ubiquitous
TNF or IL-17.
Nikamo et al. (2014) identified puta-
tive binding sites in the high-risk haplo-
type for the aryl hydrocarbon receptor
(AhR), a transcription factor involved
in promoting the differentiation of
Th22 cells (Veldhoen et al., 2008,
Ramirez et al., 2010). AhR was first
linked to xenobiotic responses to envir-
onmental materials but more recently
has been implicated in regulatory
processes that control homeostatic and
inflammatory immune responses, parti-
cularly in the gut (Ouyang, 2010). AhR
interacts with several environmental
pollutants including dioxins and poly-
cyclic aromatic hydrocarbons, such as
the ones that are found in tar, as well as
endogenous ligands including trypto-
phan metabolites, bilirubin, arachi-
donic acid metabolites, modified low-
density lipoprotein, and several dietary
carotenoids (Denison and Nagy, 2003).
One observation that the AhR regulates
inflammatory responses comes from
models of inflammatory bowel disease
(IBD) in which activation of AhR results
in inhibition of inflammatory pathways
and induction of tissue repair processes
(Ouyang, 2010). This coupled with the
observations that inhibition or genetic
knockdown of IL-22 worsen the out-
comes in models of IBD strongly
suggests, in striking contrast to its pro-
inflammatory role in psoriasis, a protec-
tive role for IL-22 in the gut (Ouyang,
2010).
Given the pro-Th22 nature of
AhR activation, how does this fit
with coal tar treatments for psoriasis?
As discussed above, IL-22 induces
many of the hallmark features of psor-
iasis on keratinocytes, yet this long-
standing and effective therapy for psor-
iasis supplies many potential AhR
ligands including polycyclic aromatic
hydrocarbons. Coal tar–mediated
activation of the AhR has been shown
to drive epidermal differentiation (van
den Bogaard et al., 2013), reversing
some of the histological characteristics
of psoriasis. Coal tar activation of AhR
in skin may also promote a pro-Th22
environment, which suppresses Th1 and
Th17 activity leading to a net reduction
of keratinocyte activation and pro-
liferation. Alternatively, moieties in the
coal tar, while being ligands for AhR,
could have antagonistic effects, dum-
bing down IL-22 and its synergistic
effects with other IL-20 and IL-17
cytokines.
Taken together, the role of IL-22 and
the AhR in psoriasis is highly complex
and still incompletely understood. The
data published by Nikamo et al. (2014)
in this issue are highly intriguing and
raise the question of why this risk
variant has more prominent role in
juvenile-onset psoriasis compared with
later-onset psoriasis. This and many
other questions remain to be answered,
but with several studies in the works
to look at clinical stratification of
existing data sets, it will be exciting to
see where this will take psoriasis gene-
tics in the coming years, and with it
our understanding of the pathology of
psoriasis.
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